| 6.02 0.02 (0.33%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.22 | 1-year : | 7.68 |
| Resists | First : | 6.18 | Second : | 6.57 |
| Pivot price | 6.06 |
|||
| Supports | First : | 5.55 | Second : | 4.62 |
| MAs | MA(5) : | 6.07 |
MA(20) : | 6.03 |
| MA(100) : | 6.14 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 41.9 |
D(3) : | 43.9 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 8.28 | Low : | 4.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ COYA ] has closed above bottom band by 43.6%. Bollinger Bands are 36.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.09 - 6.13 | 6.13 - 6.16 |
| Low: | 5.86 - 5.91 | 5.91 - 5.95 |
| Close: | 5.96 - 6.03 | 6.03 - 6.09 |
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.
Tue, 25 Nov 2025
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - Yahoo Finance
Fri, 14 Nov 2025
Chardan Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
Wed, 12 Nov 2025
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update - Business Wire
Tue, 28 Oct 2025
Here’s Greenlight Capital’s Update on Coya Therapeutics (COYA) - Yahoo Finance
Thu, 23 Oct 2025
Coya Therapeutics Announces Proposed Public Offering of Common Stock - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 22.7 (%) |
| Shares Short | 388 (K) |
| Shares Short P.Month | 280 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | 0 % |
| Operating Margin | -53.8 % |
| Return on Assets (ttm) | -37.2 % |
| Return on Equity (ttm) | -62.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.47 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -5.43 |
| PEG Ratio | 0 |
| Price to Book value | 3.69 |
| Price to Sales | 31.56 |
| Price to Cash Flow | -10.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|